icon
Go back to News
NEWS

GA_P advises Oryzon on a capital increase and a financing agreement with COFIDES

icon 9 July, 2026

Gómez-Acebo & Pombo has advised Oryzon Genomics, a biopharmaceutical company focused on epigenetics-based therapies, on a strategic transaction aimed at strengthening its financial position and accelerating the development of its clinical programmes.

The transaction involved a capital increase through the issuance of 4,444,445 new ordinary shares, enabling the company to raise €12 million. The subscription price was set at €2.70 per share.

The proceeds will be used to strengthen Oryzon’s balance sheet and accelerate the development of its acute myeloid leukaemia programme, one of the company’s key research initiatives.

In addition, Gómez-Acebo & Pombo advised Oryzon on entering into an agreement with COFIDES under which the Social Impact Fund (FIS), managed by COFIDES, has committed to invest up to €25 million in future capital increases of the company. The investment is intended to support Oryzon’s mental health programmes and remains subject to the fulfilment of certain conditions.

These transactions further strengthen Oryzon’s financial capacity to advance its research and development activities in high-impact therapeutic areas.

The team

The Gómez-Acebo & Pombo team advising the company included members of the Corporate practice: Augusto Piñel, Jacobo Palanca and Gemma Serra.

Lawyer mentioned

Augusto Piñel – Partner

Jacobo Palanca – Senior Associate

Category

Deal

Areas and sectors

Corporate and M&A

Press contact

Sandra Cuesta
Sandra Cuesta
Director of Business Development, Marketing and Communications
Sandra Cuesta
Sandra Cuesta
Director of Business Development, Marketing and Communications
icon
icon

More information about
Gómez-Acebo & Pombo

icon
icon
icon
icon